Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

  • Malinverni, R.
  • Bargay, J.
  • Marcé, Silvia
  • Garrido, A.
  • Valcarcel Ferreiras, David
  • Cabezón, Marta
  • Xicoy, Blanca
Metilació de l'ADN; Síndromes mielodisplàstiques; Factors pronòstics, Metilación del ADN; Síndromes mielodisplásicos; Factores pronósticos, DNA methylation; Myelodysplastic syndromes; Prognostic factors, Background Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates to HMA are low and there is an unmet need in finding prognostic and predictive biomarkers of treatment response and overall survival. We performed global methylation analysis of 75 patients with high-risk MDS and secondary AML who were included in CETLAM SMD-09 protocol, in which patients received HMA or intensive treatment according to age, comorbidities and cytogenetic. Results Unsupervised analysis of global methylation pattern at diagnosis did not allow patients to be differentiated according to the cytological subtype, cytogenetic groups, treatment response or patient outcome. However, after a supervised analysis we found a methylation signature defined by 200 probes, which allowed differentiating between patients responding and non-responding to azacitidine (AZA) treatment and a different methylation pattern also defined by 200 probes that allowed to differentiate patients according to their survival. On studying follow-up samples, we confirmed that AZA decreases global DNA methylation, but in our cohort the degree of methylation decrease did not correlate with the type of response. The methylation signature detected at diagnosis was not useful in treated samples to distinguish patients who were going to relapse or progress. Conclusions Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis may be useful as a biomarker for predicting AZA response and survival., This work was supported in part by a grant from Instituto de Salud Carlos III, Miniterio de Sanidad y Consumo, Spain (PI11/02519) and a grant from Celgene Spain. Research in the Buschbeck and Zamora labs is further supported by the following grants: the national grant RTI2018-094005-B-I00 from FEDER/Ministerio de Ciencia e Innovación – Agencia Estatal de Invsetigación (to MB); MINECO-ISCIII PIE16/00011 (to LZ and MB); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to MB); AGAUR 2017-SGR-305 (to LZ and MB) and Fundació La Marató de TV3 254/C/2019 (to MB). Research at the IJC is supported by the “La Caixa” Foundation, the Fundació Internacional Josep Carreras, Celgene Spain and the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç
  • Bystrup, Sara
  • Cabrero-de Las Heras, Sara
  • Musulén, Eva
  • Palomero, Luis
  • Henar Alonso, Maria
  • Arango Corro, Diego
  • Nieto Raya, Rocio
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker, Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo, Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu, In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease., This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes

  • Palau de Miguel, Anna|||0000-0003-2131-1265
  • Garz, Anne-Kathrin
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Zwick, Anabel
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Valero, Vanesa
  • Lappin, Katrina
  • Casquero, Raquel
  • Lennartsson, Andreas
  • Zuber, Johannes|||0000-0001-8810-6835
  • Navarro, Tomàs
  • Mills, Ken I.
  • Götze, Katharina S.|||0000-0002-6276-8002
  • Buschbeck, Marcus|||0000-0002-3218-4567
Genetic lesions affecting epigenetic regulators are frequent in myelodysplastic syndromes (MDS). Polycomb proteins are key epigenetic regulators of differentiation and stemness that act as two multimeric complexes termed polycomb repressive complexes 1 and 2, PRC1 and PRC2, respectively. While components and regulators of PRC2 such as ASXL1 and EZH2 are frequently mutated in MDS and AML, little is known about the role of PRC1. To analyze the role of PRC1, we have taken a functional approach testing PRC1 components in loss- and gain-of-function experiments that we found overexpressed in advanced MDS patients or dynamically expressed during normal hematopoiesis. This approach allowed us to identify the enzymatically active component RING1A as the key PRC1 component in hematopoietic stem cells and MDS. Specifically, we found that RING1A is expressed in CD34 + bone marrow progenitor cells and further overexpressed in high-risk MDS patients. Knockdown of RING1A in an MDS-derived AML cell line facilitated spontaneous and retinoic acid-induced differentiation. Similarly, inactivation of RING1A in primary CD34 + cells augmented erythroid differentiation. Treatment with a small compound RING1 inhibitor reduced the colony forming capacity of CD34 + cells from MDS patients and healthy controls. In MDS patients higher RING1A expression associated with an increased number of dysplastic lineages and blasts. Our data suggests that RING1A is deregulated in MDS and plays a role in the erythroid development defect.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD + consumption

  • Posavec Marjanović, Melanija
  • Hurtado-Bagès, Sarah|||0000-0002-6588-0876
  • Lassi, Maximilian
  • Valero, Vanesa
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Delage, Hélène
  • Navarro, Miriam
  • Corujo, David|||0000-0001-7930-0935
  • Guberovic, Iva
  • Douet, Julien
  • Gama-Pérez, Pau
  • Garcia-Roves, Pablo M.|||0000-0001-9826-1740
  • Ahel, Ivan
  • Ladurner, Andreas G.|||0000-0003-3835-232X
  • Yanes, Oscar|||0000-0003-3695-7157
  • Bouvet, Philippe|||0000-0003-4524-2233
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
  • Teperino, Raffaele
  • Pospisilik, J. Andrew
  • Buschbeck, Marcus|||0000-0002-3218-4567
Histone variants are structural components of eukaryotic chromatin that can replace replication-coupled histones in the nucleosome. The histone variant macroH2A.1.1 contains a macrodomain able to bind NAD + derived metabolites. Here, we report that macroH2A.1.1 is rapidly induced during myogenic differentiation through a switch in alternative splicing. Importantly, myotubes lacking macroH2A.1.1 display a defect in mitochondrial respiratory capacity. We find that the metabolite-interacting macrodomain is essential for sustaining optimal mitochondrial function, but dispensable for gene regulation. Through direct binding, macroH2A.1.1 inhibits basal poly-ADP ribose polymerase 1 activity and thus reduces nuclear NAD+ consumption. Consequentially, accumulation of the NAD + precursor NMN allows the maintenance of mitochondrial NAD + pools critical for respiration. Our data indicate that macroH2A.1.1-containing chromatin regulates mitochondrial respiration by limiting nuclear NAD+ consumption and establishing a buffer of NAD + precursors in differentiated cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer

  • Corujo, David|||0000-0001-7930-0935
  • Buschbeck, Marcus|||0000-0002-3218-4567
Histone variants are chromatin components that replace replication-coupled histones in a fraction of nucleosomes and confer particular characteristics to chromatin. H2A variants represent the most numerous and diverse group among histone protein families. In the nucleosomal structure, H2A-H2B dimers can be removed and exchanged more easily than the stable H3-H4 core. The unstructured N-terminal histone tails of all histones, but also the C-terminal tails of H2A histones protrude out of the compact structure of the nucleosome core. These accessible tails are the preferential target sites for a large number of post-translational modifications (PTMs). While some PTMs are shared between replication-coupled H2A and H2A variants, many modifications are limited to a specific histone variant. The present review focuses on the H2A variants H2A.Z, H2A.X, and macroH2A, and summarizes their functions in chromatin and how these are linked to cancer development and progression. H2A.Z primarily acts as an oncogene and macroH2A and H2A.X as tumour suppressors. We further focus on the regulation by PTMs, which helps to understand a degree of context dependency.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Emerging roles of macrosatellite repeats in genome organization and disease development

  • Dumbovic, Gabrijela
  • Forcales, Sònia Vanina|||0000-0002-7111-4959
  • Perucho, Manuel|||0000-0002-2169-2662
Abundant repetitive DNA sequences are an enigmatic part of the human genome. Despite increasing evidence on the functionality of DNA repeats, their biologic role is still elusive and under frequent debate. Macrosatellites are the largest of the tandem DNA repeats, located on one or multiple chromosomes. The contribution of macrosatellites to genome regulation and human health was demonstrated for the D4Z4 macrosatellite repeat array on chromosome 4q35. Reduced copy number of D4Z4 repeats is associated with local euchromatinization and the onset of facioscapulohumeral muscular dystrophy. Although the role other macrosatellite families may play remains rather obscure, their diverse functionalities within the genome are being gradually revealed. In this review, we will outline structural and functional features of coding and noncoding macrosatellite repeats, and highlight recent findings that bring these sequences into the spotlight of genome organization and disease development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial, The need for a new pre-clinical treatment rationale

  • Bracht, Jillian|||0000-0001-9552-3960
  • Karachaliou, Niki
  • Bivona, Trever
  • Lanman, Richard B.
  • Faull, Iris
  • Nagy, Rebecca J.
  • Drozdowskyj, Ana
  • Berenguer, Jordi
  • Fernandez-Bruno, Manuel
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
  • Rosell, Rafael|||0000-0003-0817-3400
BRAF V600 mutations have been found in 1-2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50-80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with impaired kinase activity, upstream signaling dependence, and consequently, sensitivity to receptor tyrosine kinase (RTK) inhibitors. Plasma cell-free DNA (cfDNA) of 185 newly diagnosed advanced lung adenocarcinoma patients (Spanish Lung Liquid versus Invasive Biopsy Program, SLLIP, NCT03248089) was examined for BRAF and other alterations with a targeted cfDNA next-generation sequencing (NGS) assay (Guardant360®, Guardant Health Inc., CA, USA), and results were correlated with patient outcome. Cell viability with single or combined RAF, MEK, and SHP2 inhibitors was assessed in cell lines with BRAF class I, II, and III mutations. Out of 185 patients, 22 had BRAF alterations (12%) of which seven patients harbored amplifications (32%) and 17 had BRAF mutations (77%). Of the BRAF mutations, four out of 22 (18%) were V600E and 18/22 (82%) were non-V600. In vitro results confirmed sensitivity of class III and resistance of class I and II BRAF mutations, and BRAF wild type cells to SHP2 inhibition. Concomitant MEK or RAF and SHP2 inhibition showed synergistic effects, especially in the class III BRAF-mutant cell line. Our study indicates that the class of the BRAF mutation may have clinical implications and therefore should be defined in the clinical practice and used to guide therapeutic decisions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Bystrup, Sara|||0000-0002-7971-0851
  • Cabrero de las Heras, Sara
  • Musulén, Eva|||0000-0002-9667-6464
  • Palomero, Luis|||0000-0002-9144-1017
  • Alonso, María Henar
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Arango, Diego|||0000-0003-2953-3284
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Queralt, C.|||0000-0001-9875-0173
  • Manzano Mozo, José Luís
  • Layos, Laura
  • Bugés, Cristina|||0000-0003-2013-1510
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia

  • Maher, Michael|||0000-0002-4956-7185
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Casquero, Raquel
  • Buschbeck, Marcus|||0000-0002-3218-4567
In recent years fatty acid metabolism has gained greater attention in haematologic cancers such as acute myeloid leukaemia. The oxidation of fatty acids provides fuel in the form of ATP and NADH, while fatty acid synthesis provides building blocks for cellular structures. Here, we will discuss how leukaemic cells differ from healthy cells in their increased reliance on fatty acid metabolism. In order to understand how these changes are achieved, we describe the main pathways regulating fatty acid metabolism at the transcriptional level and highlight the limited knowledge about related epigenetic mechanisms. We explore these mechanisms in the context of leukaemia and consider the relevance of the bone marrow microenvironment in disease management. Finally, we discuss efforts to interfere with fatty acid metabolism as a therapeutic strategy along with the use of metabolic parameters as biomarkers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

  • Cabezón, Marta|||0000-0001-5122-7481
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Bargay, Joan|||0000-0002-6739-3916
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Marcé, Silvia|||0000-0001-9128-6822
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Tormo, Mar|||0000-0001-9622-1649
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Coll, Rosa|||0000-0003-0560-1254
  • Borrás, Josep
  • Jiménez, María José|||0000-0002-5469-5237
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Valcárcel, David|||0000-0002-8747-078X
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Font, L. L.
  • Ramila, Elena
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Zamora, Lurdes|||0000-0003-1713-7110
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates to HMA are low and there is an unmet need in finding prognostic and predictive biomarkers of treatment response and overall survival. We performed global methylation analysis of 75 patients with high-risk MDS and secondary AML who were included in CETLAM SMD-09 protocol, in which patients received HMA or intensive treatment according to age, comorbidities and cytogenetic. Unsupervised analysis of global methylation pattern at diagnosis did not allow patients to be differentiated according to the cytological subtype, cytogenetic groups, treatment response or patient outcome. However, after a supervised analysis we found a methylation signature defined by 200 probes, which allowed differentiating between patients responding and non-responding to azacitidine (AZA) treatment and a different methylation pattern also defined by 200 probes that allowed to differentiate patients according to their survival. On studying follow-up samples, we confirmed that AZA decreases global DNA methylation, but in our cohort the degree of methylation decrease did not correlate with the type of response. The methylation signature detected at diagnosis was not useful in treated samples to distinguish patients who were going to relapse or progress. Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis may be useful as a biomarker for predicting AZA response and survival.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The taming of PARP1 and its impact on NAD+ metabolism

  • Hurtado-Bagès, Sarah|||0000-0002-6588-0876
  • Knobloch, G.
  • Ladurner, Andreas G.|||0000-0003-3835-232X
  • Buschbeck, Marcus|||0000-0002-3218-4567
Background: Poly-ADP-ribose polymerases (PARPs) are key mediators of cellular stress response. They are intimately linked to cellular metabolism through the consumption of NAD. PARP1/ARTD1 in the nucleus is the major NAD consuming activity and plays a key role in maintaining genomic integrity. Scope of review: In this review, we discuss how different organelles are linked through NAD metabolism and how PARP1 activation in the nucleus can impact the function of distant organelles. We discuss how differentiated cells tame PARP1 function by upregulating an endogenous inhibitor, the histone variant macroH2A1.1. Major conclusions: The presence of macroH2A1.1, particularly in differentiated cells, raises the threshold for the activation of PARP1 with consequences for DNA repair, gene transcription, and NAD homeostasis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Histone Variant MacroH2A1 Regulates Key Genes for Myogenic Cell Fusion in a Splice-Isoform Dependent Manner

  • Hurtado-Bagès, Sarah|||0000-0002-6588-0876
  • Posavec Marjanovic, Melanija
  • Valero, Vanesa
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Corujo, David|||0000-0001-7930-0935
  • Bouvet, Philippe|||0000-0003-4524-2233
  • Lavigne, A. C.|||0000-0001-9389-7029
  • Bystricky, K.|||0000-0001-6717-3721
  • Buschbeck, Marcus|||0000-0002-3218-4567
MacroH2A histone variants have functions in differentiation, somatic cell reprogramming and cancer. However, at present, it is not clear how macroH2As affect gene regulation to exert these functions. We have parted from the initial observation that loss of total macroH2A1 led to a change in the morphology of murine myotubes differentiated ex vivo. The fusion of myoblasts to myotubes is a key process in embryonic myogenesis and highly relevant for muscle regeneration after acute or chronic injury. We have focused on this physiological process, to investigate the functions of the two splice isoforms of macroH2A1. Individual perturbation of the two isoforms in myotubes forming in vitro from myogenic C2C12 cells showed an opposing phenotype, with macroH2A1.1 enhancing, and macroH2A1.2 reducing, fusion. Differential regulation of a subset of fusion-related genes encoding components of the extracellular matrix and cell surface receptors for adhesion correlated with these phenotypes. We describe, for the first time, splice isoform-specific phenotypes for the histone variant macroH2A1 in a physiologic process and provide evidence for a novel underlying molecular mechanism of gene regulation.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The MacroH2A1.1 - PARP1 Axis at the Intersection Between Stress Response and Metabolism

  • Hurtado-Bagès, Sarah|||0000-0002-6588-0876
  • Guberovic, Iva
  • Buschbeck, Marcus|||0000-0002-3218-4567
The exchange of replication-coupled canonical histones by histone variants endows chromatin with specific features. The replacement of the canonical H2A histone for the histone variant macroH2A is one of the most remarkable epigenetic modifications. The three vertebrate macroH2A proteins have a unique tripartite structure consisting of H2A-like domain, unstructured linker, and macrodomain. Macrodomains are ancient globular folds that are able to bind nicotinamide adenine dinucleotide (NAD +) derived metabolites. Here, we will briefly describe the physiological relevance of the metabolite binding in the context of chromatin. In particular, we will focus on the macroH2A1.1 isoform that binds ADP-ribose and poly-ADP-ribose polymerase 1 (PARP1) enzyme, a cellular stress sensor. We will discuss the impact of this interaction in the context of cancer, senescence, cell stress and energy metabolism.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Poly(Adp-ribose) binding and macroh2a mediate recruitment and functions of kdm5a at dna lesions

  • Kumbhar, Ramhari
  • Sanchez, Anthony
  • Perren, Jullian
  • Gong, Fade
  • Corujo, David|||0000-0001-7930-0935
  • Medina, Frank
  • Devanathan, Sravan K.
  • Xhemalce, Blerta
  • Matouschek, Andreas
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Buck-Koehntop, Bethany A.
  • Miller, Kyle M.
The histone demethylase KDM5A erases histone H3 lysine 4 methylation, which is involved in transcription and DNA damage responses (DDRs). While DDR functions of KDM5A have been identified, how KDM5A recognizes DNA lesion sites within chromatin is unknown. Here, we identify two factors that act upstream of KDM5A to promote its association with DNA damage sites. We have identified a noncanonical poly(ADP-ribose) (PAR)-binding region unique to KDM5A. Loss of the PARbinding region or treatment with PAR polymerase (PARP) inhibitors (PARPi's) blocks KDM5A-PAR interactions and DNA repair functions of KDM5A. The histone variant macroH2A1.2 is also specifically required for KDM5A recruitment and function at DNA damage sites, including homology-directed repair of DNA double-strand breaks and repression of transcription at DNA breaks. Overall, this work reveals the importance of PAR binding and macroH2A1.2 in KDM5A recognition of DNA lesion sites that drive transcriptional and repair activities at DNA breaks within chromatin that are essential for maintaining genome integrity
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David|||0000-0001-7930-0935
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Meers, Oliver|||0000-0001-9532-7767
  • Garcia-Jaraquemada, Arce|||0000-0001-6603-2003
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Valero, Vanesa
  • Pérez, Ainoha
  • Del Río-Álvarez, Álvaro|||0000-0003-2338-0782
  • Royo, Laura|||0000-0001-5770-2001
  • Pérez-González, Beatriz|||0000-0001-9849-5176
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Acemel, Rafael D.|||0000-0003-4120-0140
  • Santos-Pereira, José M.|||0000-0003-3949-0644
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Gómez-Skarmeta, José Luís|||0000-0001-5125-4332
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Manyé, Josep|||0000-0002-3121-8016
  • Armengol, Carolina|||0000-0002-4690-4027
  • Buschbeck, Marcus|||0000-0002-3218-4567
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18

  • Maher, Michael|||0000-0002-4956-7185
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Cabezón, Marta|||0000-0001-5122-7481
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Vergara, Sara
  • Méndez López, Aleix
  • Mesa Tudel, Alba|||0000-0002-8377-7573
  • Sole, F.|||0000-0002-3251-2161
  • Sorigue, Marc|||0000-0002-0587-591X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Granada, Isabel|||0000-0002-4275-0104
  • Buschbeck, Marcus|||0000-0002-3218-4567
Haematopoietic malignancies are frequently characterized by karyotypic abnormalities. The development of targeted drugs has been pioneered with compounds against gene products of fusion genes caused by chromosomal translocations. While polysomies are equally frequent as translocations, for many of them we are lacking therapeutic approaches aimed at synthetic lethality. Here, we report two new cell lines, named MBU-7 and MBU-8, that differ in complete trisomy of chromosome18, a partial trisomy of chromosome 7 and a tetrasomy of the p-arm of chromosome 8, but otherwise share the same mutational pattern and complex karyotype. Both cell lines are divergent clones of U-937 cells and have the morphology and immunoprofile of monocytic cells. The distinct karyotypic differences between MBU-7 and MBU-8 are associated with a difference in the specific response to nucleoside analogues. Taken together, we propose the MBU-7 and MBU-8 cell lines described here as suitable in vitro models for screening and testing vulnerabilities that are associated with the disease-relevant polysomies of chromosome 7, 8 and 18.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis

  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Winkler, René|||0000-0002-7570-0242
  • Casquero, Raquel
  • Muhar, Matthias|||0000-0002-3018-9698
  • van der Garde, Mark
  • Maher, Michael|||0000-0002-4956-7185
  • Martínez Herráez, Carolina|||0000-0003-4711-7225
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Fellner, Michaela
  • Rathert, Philipp|||0000-0003-1477-136X
  • Brooks, Nigel
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Gentilella, Antonio|||0000-0002-6830-2086
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Zuber, Johannes|||0000-0001-8810-6835
  • Götze, Katharina S.|||0000-0002-6276-8002
  • Buschbeck, Marcus|||0000-0002-3218-4567
The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. New treatment options are urgently needed to improve the clinical management of these patients. Here, we perform a loss-of-function shRNA screen and identify the histone acetyl transferase and transcriptional co-activator, CREB binding protein (CBP), as a major regulator of AZA sensitivity. Compounds inhibiting the activity of CBP and the closely related p300 synergistically reduce viability of MDS-derived AML cell lines when combined with AZA. Importantly, this effect is specific for the RNA-dependent functions of AZA and not observed with the related compound decitabine that is only incorporated into DNA. The identification of immediate target genes leads us to the unexpected finding that the effect of CBP/p300 inhibition is mediated by globally down regulating protein synthesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of macroh2a histone variants in cancer

  • Hsu, Chen-Jen
  • Meers, Oliver|||0000-0001-9532-7767
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Heidel, Florian H.|||0000-0003-2438-1955
The epigenome regulates gene expression and provides a molecular memory of cellular events. A growing body of evidence has highlighted the importance of epigenetic regulation in physiological tissue homeostasis and malignant transformation. Among epigenetic mechanisms, the replacement of replication-coupled histones with histone variants is the least understood. Due to differences in protein sequence and genomic distribution, histone variants contribute to the plasticity of the epigenome. Here, we focus on the family of macroH2A histone variants that are partic-ular in having a tripartite structure consisting of a histone fold, an intrinsically disordered linker and a globular macrodomain. We discuss how these domains mediate different molecular functions related to chromatin architecture, transcription and DNA repair. Dysregulated expression of macroH2A histone variants has been observed in different subtypes of cancer and has variable prognostic impact, depending on cellular context and molecular background. We aim to provide a concise review regarding the context-and isoform-dependent contributions of macroH2A histone variants to cancer development and progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetics in a spectrum of myeloid diseases and its exploitation for therapy

  • Maher, Michael|||0000-0002-4956-7185
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Buschbeck, Marcus|||0000-0002-3218-4567
Mutations in genes encoding chromatin regulators are early events contributing to de-veloping asymptomatic clonal hematopoiesis of indeterminate potential and its frequent progression to myeloid diseases with increasing severity. We focus on the subset of myeloid diseases encompassing myelodysplastic syndromes and their transformation to secondary acute myeloid leukemia. We introduce the major concepts of chromatin regulation that provide the basis of epigenetic regulation. In greater detail, we discuss those chromatin regulators that are frequently mutated in myelodysplastic syndromes. We discuss their role in the epigenetic regulation of normal hematopoiesis and the consequence of their mutation. Finally, we provide an update on the drugs interfering with chromatin regulation approved or in development for myelodysplastic syndromes and acute myeloid leukemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disruption of paternal circadian rhythm affects metabolic health in male offspring via nongerm cell factors

  • Lassi, Maximilian
  • Tomar, Archana
  • Comas-Armangué, Gemma
  • Vogtmann, Rebekka
  • Dijkstra, Dorieke J.
  • Corujo, David|||0000-0001-7930-0935
  • Gerlini, Raffaelle
  • Darr, Jonatan
  • Scheid, Fabienne
  • Rozman, Jan|||0000-0002-8035-8904
  • Aguilar-Pimentel, Antonio
  • Koren, Omry
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Fuchs, Helmut|||0000-0002-5143-2677
  • Marschall, Susan
  • Gailus-Durner, Valerie
  • De Angelis, Martin Hrabe|||0000-0002-7898-2353
  • Plösch, Torsten
  • Gellhaus, Alexandra
  • Teperino, Raffaele
Circadian rhythm synchronizes each body function with the environment and regulates physiology. Disruption of normal circadian rhythm alters organismal physiology and increases disease risk. Recent epidemiological data and studies in model organisms have shown that maternal circadian disruption is important for offspring health and adult phenotypes. Less is known about the role of paternal circadian rhythm for offspring health. Here, we disrupted circadian rhythm in male mice by night-restricted feeding and showed that paternal circadian disruption at conception is important for offspring feeding behavior, metabolic health, and oscillatory transcription. Mechanistically, our data suggest that the effect of paternal circadian disruption is not transferred to the offspring via the germ cells but initiated by corticosterone-based parental communication at conception and programmed during in utero development through a state of fetal growth restriction. These findings indicate paternal circadian health at conception as a newly identified determinant of offspring phenotypes.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

  • Malinverni, R.
  • Bargay, J.
  • Marcé, Silvia
  • Garrido, A.
  • Valcarcel Ferreiras, David
  • Cabezón, Marta
  • Xicoy, Blanca
Metilació de l'ADN; Síndromes mielodisplàstiques; Factors pronòstics, Metilación del ADN; Síndromes mielodisplásicos; Factores pronósticos, DNA methylation; Myelodysplastic syndromes; Prognostic factors, Background Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates to HMA are low and there is an unmet need in finding prognostic and predictive biomarkers of treatment response and overall survival. We performed global methylation analysis of 75 patients with high-risk MDS and secondary AML who were included in CETLAM SMD-09 protocol, in which patients received HMA or intensive treatment according to age, comorbidities and cytogenetic. Results Unsupervised analysis of global methylation pattern at diagnosis did not allow patients to be differentiated according to the cytological subtype, cytogenetic groups, treatment response or patient outcome. However, after a supervised analysis we found a methylation signature defined by 200 probes, which allowed differentiating between patients responding and non-responding to azacitidine (AZA) treatment and a different methylation pattern also defined by 200 probes that allowed to differentiate patients according to their survival. On studying follow-up samples, we confirmed that AZA decreases global DNA methylation, but in our cohort the degree of methylation decrease did not correlate with the type of response. The methylation signature detected at diagnosis was not useful in treated samples to distinguish patients who were going to relapse or progress. Conclusions Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis may be useful as a biomarker for predicting AZA response and survival., This work was supported in part by a grant from Instituto de Salud Carlos III, Miniterio de Sanidad y Consumo, Spain (PI11/02519) and a grant from Celgene Spain. Research in the Buschbeck and Zamora labs is further supported by the following grants: the national grant RTI2018-094005-B-I00 from FEDER/Ministerio de Ciencia e Innovación – Agencia Estatal de Invsetigación (to MB); MINECO-ISCIII PIE16/00011 (to LZ and MB); the Deutsche José Carreras Leukämie Stiftung DJCLS 14R/2018 (to MB); AGAUR 2017-SGR-305 (to LZ and MB) and Fundació La Marató de TV3 254/C/2019 (to MB). Research at the IJC is supported by the “La Caixa” Foundation, the Fundació Internacional Josep Carreras, Celgene Spain and the CERCA Programme/Generalitat de Catalunya.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç
  • Bystrup, Sara
  • Cabrero-de Las Heras, Sara
  • Musulén, Eva
  • Palomero, Luis
  • Henar Alonso, Maria
  • Arango Corro, Diego
  • Nieto Raya, Rocio
Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker, Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo, Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu, In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease., This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.